Chemours CO 8-K filings

The Chemours Company has appointed Livingston Tony Satterthwaite to its Board of Directors, effective June 12, 2024, increasing the board size to ten members.

The Chemours Company has appointed Shane Hostetter as its new Chief Financial Officer, effective July 1, 2024, succeeding interim CFO Matthew Abbott.

Chemours has temporarily halted production at its Altamira, Mexico, titanium dioxide facility due to a severe drought and government request to minimize water intake.

The Chemours Company held its annual meeting on May 21, 2024, where shareholders elected all director nominees, approved executive compensation, and ratified the selection of PricewaterhouseCoopers LLP as the independent auditor.

Chemours' first quarter 2024 results show a decline in net sales and income compared to the previous year, though some segments showed resilience and cost-cutting measures provided some offset.

Jonathan S. Lock has resigned from his position as CFO of Chemours, with a separation agreement detailing the terms of his departure.

Chemours reported mixed Q4 2023 results, highlighting cost-saving initiatives and growth opportunities amidst market challenges and leadership changes.

Chemours has completed its internal review, revealing delayed payments and accelerated receivables, along with material weaknesses in internal controls.

Chemours' fourth quarter results showed a slight increase in sales and improved profitability, while full-year results were impacted by market destocking and litigation charges.

Chemours will release its fourth quarter and full year 2023 financial results after market close on March 27, 2024, followed by a conference call on March 28, 2024.

Chemours has appointed Denise Dignam as its new President and CEO, effective immediately, succeeding Mark Newman who has resigned.

Chemours has received a notice from the New York Stock Exchange for failing to file its annual report on time, putting the company at risk of delisting if the issue is not resolved within six months.

An internal review at Chemours uncovered that senior management manipulated cash flow figures by delaying payments and accelerating receivables, leading to a lack of transparency with the Board of Directors.

Chemours has appointed interim CEO and CFO, placed previous executives on leave, and delayed its Q4 2023 earnings release and 10-K filing due to an internal review.

Chemours has appointed an interim CEO and CFO, placing the previous executives on administrative leave pending an audit committee review.

Chemours has appointed Alister Cowan to the Audit Committee and the newly formed Environmental, Health, and Safety & Operational Performance Committee.

The Chemours Company has announced that Sandra P. Rogers will not seek re-election to the board, and Pamela F. Fletcher has been appointed as a new director, effective March 1, 2024.

Chemours has delayed its Q4 and full-year 2023 financial results release and conference call due to the need for additional time to complete its year-end reporting process and an internal control review.